Category Patents/Designs/Trade Secrets

Patenting Artificial Intelligence Might Hamper Progress, EFF Says

The Electronic Frontier Foundation launched a project last year to measure progress in artificial intelligence innovations and understand the legal, political, and technical issues potentially raised by those inventions. Some eight months later, the project has tracked rapid progress of those technologies, in particular in machine learning. According to the foundation, patents might be hampering the progress of artificial intelligence, and with the risk of patent trolls claiming rights on patents on machine learning systems.

Professor Tells UN, Governments Of Coming “Tsunami” Of Data And Artificial Intelligence

NEW YORK -- Technology is moving so fast it could cause harm to humans even as it brings remarkable advances unless governments act, an Israeli professor and visionary thinker told a gathering of government and United Nations representatives here last week. A hint? In the next five years we are all going to be cyborgs. In fact most of us already are.

USPTO Anticipates Slight Decline In Patent Filings, Including For PCT

The United States Patent and Trademark Office (USPTO) is predicting a slight decline in some patent filings for 2018 and 2019, including through the international Patent Cooperation Treaty (PCT) managed by the World Intellectual Property Organization. Trademarks, meanwhile, will likely see slowing growth.

US 2019 Budget Proposal Shows Stable Funding For WIPO, WTO, WHO, ITU

While the Trump administration has taken aim overall at US contributions to international organisations since taking office last year, the budget proposal it put forward last week would roughly maintain last year's lower levels for a range of Geneva-based agencies without making further cuts. Others did not fare as well.

WHO Names High-Profile Commission On Non-Communicable Diseases

The World Health Organization today announced a new high-level commission of heads of state, ministers and other leaders in health and development to come up with "bold and innovative solutions" against non-communicable diseases such as heart and respiratory diseases, cancers and diabetes. The chairs of the commission include the presidents of Uruguay, Sri Lanka, and Finland, the Russian health minister, and a former minister of Pakistan who was a candidate for director general of the WHO. They are joined by nearly two dozen others, including corporate public figures Michael Bloomberg and Jack Ma.

Interview With Peter Vanderheyden, CEO Of Article One Partners

Article One Partners (AOP), the world leader in crowdsourced intellectual property research, is now into their 10th year. Intellectual Property Watch recently arranged an interview with Article One Partners CEO Peter Vanderheyden to get an update on how the company has evolved in response to the ever-changing IP landscape, and in light of their commitment to IP quality.

Indian Pharma Industry Disputes US Industry IP Index

The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving".

CARB-X Announces First Award Of 2018; Seeks Partners For Antibacterial Research

CARB-X, the private-public partnership for research on antimicrobial resistance, today announced its first award of 2018, nearly $2 million for the development of a new class of antibiotics. Meanwhile, the group has announced it is seeking to partner with accelerator organisations to build its pipeline of early development research projects. It also announced a study that called for a new global approach and greater financial incentives for antibiotic research.

Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t

The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue.

Do We Need A Global Body To Set Priorities For Diseases And Research?

A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level.